Reduction of asthma exacerbations after escalation from BUD/FORM or FP/SAL to FF/UMEC/VI

Résumé fourni par la source

Rationale ICS/LABA is recommended for patients with asthma, with BUD/FORM and FP/SAL commonly used before escalation to FF/UMEC/VI. Real-world evidence on the effectiveness of FF/UMEC/VI on exacerbations, stratified by prior ICS/LABA used (BUD/FORM or FP/SAL), was evaluated for patients with asthma in the US. Methods Retrospective pre-post outcomes were assessed using Komodo Health Database claims data (09/2019–12/2023). The index date was the first FF/UMEC/VI pharmacy claim. Adults with asthma, ≥12 months continuous insurance pre-/post-initiation and ≥30 consecutive days ICS/LABA (BUD/FORM or FP/SAL) use pre-initiation were included. Asthma-related exacerbations were evaluated using rate ratios (RRs; 95% CIs) from Poisson regression. Results Of 11,522 patients (mean age 50 years; 70% female), 6073 (53%) last used BUD/FORM and 5449 (47%) used FP/SAL. Overall exacerbations were significantly reduced regardless of prior ICS/LABA (38%; RR [95% CI]: 0.62 [0.60, 0.64]). When stratified by formulation, exacerbations were significantly reduced by 39% for BUD/FORM (0.61 [0.58, 0.63]) and 37% for FP/SAL (0.63 [0.60, 0.66]). Reductions were consistent across IP/ED visits and systemic corticosteroid utilisation (Figure). Conclusions Patients who escalate to FF/UMEC/VI from ICS/LABA significantly reduced asthma exacerbations irrespective of prior BUD/FORM or FP/SAL treatment. Funding GSK (300181). erj;66/suppl_69/PA4643/F1 F1 F1

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.